Journal
AGING CLINICAL AND EXPERIMENTAL RESEARCH
Volume 25, Issue -, Pages S137-S141Publisher
SPRINGER
DOI: 10.1007/s40520-013-0127-5
Keywords
Osteoporosis; Persistence; Database; Drug utilization
Categories
Ask authors/readers for more resources
The aim of our retrospective cohort study is to analyze the persistence rates in relation to antiosteoporotic drugs using administrative databases in the Campania Region. Patients, aged >= 40 years, were included if at least one prescription for any antiosteoporotic drugs had been filled in between January 1, 2009 and December 31, 2009. Overall, 37,594 patients were incident users of antiosteoporotic drugs. Among them, 15,978 patients had undergone spot-therapies. A total of 2,618 (14.1 %) were classified as switchers. Switching rates were highest for patients taking Alendronate 18.9 or Strontium Ranelate 15.0 and lower for patients taking Ibandronate 12.8 or Risedronate 10.8. In the overall population, 33.5 % of subjects were still on therapy after 6 months. At 1 year, persistence rates were: Ibandronate 21.6 %, Risedronate 15.8 %, Alendronate + Vitamin D 15.7 %, Raloxifene 14.3 %, Alendronate 12.6 % and Strontium Ranelate 5.0 %.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available